NASDAQ:NVCR - Novocure Stock Price, News, & Analysis

Sign in or create an account to add this stock to your watchlist.
$45.01 -0.25 (-0.55 %)
(As of 01/17/2019 12:03 PM ET)
Previous Close$45.26
Today's Range$44.82 - $45.66
52-Week Range$19.06 - $53.70
Volume13,762 shs
Average Volume650,914 shs
Market Capitalization$4.14 billion
P/E Ratio-64.37
Dividend YieldN/A
Beta2.86
Novocure Ltd. operates as an oncology company. It enages in developing its propriety technoclogy, Tumor Treating Fields, which uses electric fields tuned to specific frequencies to disrupt cancer cell division, inhibiting tumor growth, and causing affected cancer cells to die. The company was founded by Yoram Palti in 2000 and is headquartered in St. Helier, Jersey.

Receive NVCR News and Ratings via Email

Sign-up to receive the latest news and ratings for NVCR and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Surgical & medical instruments
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:NVCR
CUSIPN/A
Phone44-0-15-3475-6700

Debt

Current Ratio6.17
Quick Ratio5.72

Price-To-Earnings

Sales & Book Value

Annual Sales$177.03 million
Price / Sales23.65
Price / Cash FlowN/A
Book Value$1.27 per share
Price / Book35.44

Profitability

Net Income$-61,660,000.00
Net Margins-25.37%
Return on Assets-19.72%

Miscellaneous

Employees495
Market Cap$4.14 billion
OptionableOptionable

Novocure (NASDAQ:NVCR) Frequently Asked Questions

What is Novocure's stock symbol?

Novocure trades on the NASDAQ under the ticker symbol "NVCR."

How were Novocure's earnings last quarter?

Novocure Ltd (NASDAQ:NVCR) issued its earnings results on Thursday, October, 25th. The medical equipment provider reported ($0.13) EPS for the quarter, topping the consensus estimate of ($0.15) by $0.02. The medical equipment provider had revenue of $64.76 million for the quarter, compared to the consensus estimate of $65.61 million. Novocure had a negative net margin of 25.37% and a negative return on equity of 52.72%. View Novocure's Earnings History.

When is Novocure's next earnings date?

Novocure is scheduled to release their next quarterly earnings announcement on Thursday, February 28th 2019. View Earnings Estimates for Novocure.

What guidance has Novocure issued on next quarter's earnings?

Novocure updated its fourth quarter 2018 earnings guidance on Monday, January, 7th. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $69.6-69.6 million, compared to the consensus revenue estimate of $70.47 million.

What price target have analysts set for NVCR?

6 equities research analysts have issued 1-year target prices for Novocure's stock. Their forecasts range from $36.00 to $58.00. On average, they anticipate Novocure's share price to reach $46.50 in the next twelve months. This suggests a possible upside of 3.3% from the stock's current price. View Analyst Price Targets for Novocure.

What is the consensus analysts' recommendation for Novocure?

6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Novocure in the last year. There are currently 2 hold ratings and 4 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Novocure.

What are Wall Street analysts saying about Novocure stock?

Here are some recent quotes from research analysts about Novocure stock:
  • 1. According to Zacks Investment Research, "NovoCure Limited is an oncology company. The Company is engaged in developing a therapy called Tumor Treating Fields for the treatment of solid tumor cancers. It operates primarily in the United States, Germany, Switzerland and Japan. NovoCure Limited is based in Saint Helier, Channel Islands. " (12/29/2018)
  • 2. Mizuho analysts commented, "We currently model initial revenue for this indication starting in late 2019." (12/6/2018)

Has Novocure been receiving favorable news coverage?

News articles about NVCR stock have been trending positive on Thursday, according to InfoTrie. The research group ranks the sentiment of news coverage by reviewing more than six thousand blog and news sources. The firm ranks coverage of companies on a scale of -5 to 5, with scores closest to five being the most favorable. Novocure earned a media sentiment score of 2.6 on InfoTrie's scale. They also gave news articles about the medical equipment provider a news buzz of 8.0 out of 10, indicating that recent news coverage is very likely to have an effect on the company's share price in the immediate future.

Who are some of Novocure's key competitors?

Who are Novocure's key executives?

Novocure's management team includes the folowing people:
  • Asaf Danziger, Chief Executive Officer & Director
  • Mike Ambrogi, Chief Operating Officer
  • Wilco Groenhuysen, CFO & Principal Accounting Officer
  • Eilon D. Kirson, Chief Science Officer, Head-Research & Development
  • Pritesh Shah, Chief Commercial Officer

How do I buy shares of Novocure?

Shares of NVCR can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Novocure's stock price today?

One share of NVCR stock can currently be purchased for approximately $45.01.

How big of a company is Novocure?

Novocure has a market capitalization of $4.14 billion and generates $177.03 million in revenue each year. The medical equipment provider earns $-61,660,000.00 in net income (profit) each year or ($0.70) on an earnings per share basis. Novocure employs 495 workers across the globe.

What is Novocure's official website?

The official website for Novocure is http://www.novocure.com.

How can I contact Novocure?

Novocure's mailing address is LE MASURIER HOUSE LA RUE LE MASURIER, ST. HELIER Y9, JE2 4YE. The medical equipment provider can be reached via phone at 44-0-15-3475-6700 or via email at [email protected]


MarketBeat Community Rating for Novocure (NASDAQ NVCR)

Community Ranking:  2.6 out of 5 (star star)
Outperform Votes:  304 (Vote Outperform)
Underperform Votes:  272 (Vote Underperform)
Total Votes:  576
MarketBeat's community ratings are surveys of what our community members think about Novocure and other stocks. Vote "Outperform" if you believe NVCR will outperform the S&P 500 over the long term. Vote "Underperform" if you believe NVCR will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 1/17/2019 by MarketBeat.com Staff

Featured Article: Dividend Aristocrat Index

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel